InPhamed
- Company typePrivate
- Founded2021
- HeadquartersNew Delhi, India
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
InPhamed firmographics
Firmographics- Name
- InPhamed
- Legal name
- InPhamed
- Website
- https://inphamed.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
InPhamed industry classification
Industry- Product category
- Pharmaceutical Intelligence Software
- NAICS
- Marketing Research and Public Opinion Polling (541910)
- akta.pro primary industry
- Healthcare Terminology, Ontology & Code Set Management (SNOMED/LOINC/ICD/RxNorm) (HLACAIAF)
- akta.pro secondary industry
- Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)
Keywords
Where InPhamed is headquartered
LocationHeadquarters
- HQ city
- New Delhi
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
InPhamed business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Subscription Access to Platform: Customers subscribe to access the InPhamed platform and its suite of products including Generic Insights, Clinical Insights, and consulting services. Subscribers can use a mix of products and custom services as part of their subscription.
- Custom Consulting Services: Bespoke consulting engagements delivering custom reports, market forecasts, epidemiology estimates, patent search and analytics, and other project-based professional services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Subscription-based access to platform and consulting services |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
InPhamed product offering
Product offeringCore offering
InPhamed provides a subscription-based pharmaceutical intelligence platform covering intellectual property, clinical trials, drug treatments, regulatory landscapes, and commercial markets, with three product lines: Generic Insights (drug portfolio building, patent exclusivity tracking, and API manufacturer identification), Clinical Insights (real-time R&D and clinical trial analytics), and Consulting Services (bespoke market intelligence, epidemiology, real-world evidence, and patent analytics). The platform applies AI and advanced analytics to cleaned health data to support product selection, launch planning, and competitive monitoring for pharmaceutical companies, CROs, and API manufacturers.
Product overview
InPhamed offers a unified pharmaceutical intelligence platform with three integrated products: Generic Insights for market performance, patent, and API manufacturing data; Clinical Insights for real-time R&D and clinical trial analytics; and Consulting Services as an add-on module providing specialized expertise in market intelligence, epidemiology, and patent analytics. The platform serves pharmaceutical companies, clinical research organizations, and API manufacturers with actionable intelligence across intellectual property, clinical trials, drug treatments, regulatory landscapes, and commercial markets.
Differentiator
Problem solved
Functional benefit
Brands
- InPhamed Generic Insights: Comprehensive solutions to help pharmaceutical companies identify, launch, and manage generic products successfully, including deep analysis on product selection, competitor activity, and protection status.
- InPhamed Clinical Insights
- InPhamed Consulting Services
Products and services
- InPhamed Generic Insights
Quantifiable outcome
- 1000+ drugs tracked for generic launch planning across US, Europe and ROW markets
- +2 more outcomes
Companies that use InPhamed
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
InPhamed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
InPhamed partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights4 records
InPhamed competitors and assessment
Company assessmentBroad incumbents
- Adis (Springer Nature): Pharma information services arm of Springer Nature offering drug pipelines, clinical trials, and treatment insights. Comparable to InPhamed's clinical and commercial intelligence offerings, particularly for R&D-focused customers.
- GlobalData: Large-scale data and analytics provider offering pharma intelligence across drug pipelines, clinical trials, epidemiology, and market forecasting. Comparable to InPhamed across clinical and commercial intelligence use cases, but with substantially broader coverage and resources.
- Clarivate Analytics: Global information services and analytics firm covering pharma IP, clinical trials, and competitive intelligence (e.g., Cortellis, Derwent, DRG). Directly comparable as InPhamed targets overlapping use cases for generic launch planning, patent exclusivity analysis, and clinical trial intelligence, but operates at vastly larger scale.
- Citeline (formerly Pharma Intelligence / Informa): Provides clinical trial intelligence (TrialTrove), drug pipeline data (Pharmaprojects), and competitive pharma intelligence via Trialtrove, Sitetrove, and PharmaProjects. Highly comparable to InPhamed's Clinical Insights product and overall pharma intelligence offering.
- Evaluate Pharma: Provides pharma commercial intelligence, including drug forecasts, pipeline analysis, and deal-making data. Comparable to InPhamed's market intelligence and forecasting capabilities, though with deeper coverage in branded drug analytics versus generic focus.
Direct peers
- PharmaCircle: Pharma industry intelligence platform covering drug pipelines, API sourcing, patents, and competitive intelligence across pharma and biopharma. Closely aligned with InPhamed's generic launch and API manufacturer identification use cases.
- IPD Analytics: Specialty pharma intelligence firm providing drug launch analytics, exclusivity tracking, and API sourcing data for generic and specialty drug manufacturers. Closely aligned with InPhamed's Generic Insights product, and notably InPhamed's co-founder Neetan Gour previously served as Country Director for IPD Analytics in India and APAC.
- DrugPatentWatch: Specialty platform focused on pharmaceutical patent and exclusivity intelligence, including patent expiration tracking and generic launch timing — directly comparable to a core component of InPhamed's Generic Insights product.
Regional players
- Definitive Healthcare: Provides healthcare commercial intelligence and analytics, primarily focused on the US market. Comparable as an analytics platform serving pharma and life sciences commercial teams, though with a US-centric and broader healthcare focus versus InPhamed's global generic-drug specialization.
Emerging players
- Beacon Targeted Therapies: Niche pharma competitive intelligence platform focused on oncology drug pipelines and competitive landscape analysis. Comparable as an emerging specialty intelligence platform serving pharma customers with curated clinical and commercial data.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
InPhamed social profiles
Digital presenceInPhamed financial estimates
Financial estimateRevenue estimate
Valuation estimate
InPhamed leadership team
Management profileNumber of profiles
Profiles5 records
InPhamed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InPhamed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InPhamed
What does InPhamed do?
InPhamed provides a subscription-based pharmaceutical intelligence platform covering intellectual property, clinical trials, drug treatments, regulatory landscapes, and commercial markets, with three product lines: Generic Insights (drug portfolio building, patent exclusivity tracking, and API manufacturer identification), Clinical Insights (real-time R&D and clinical trial analytics), and Consulting Services (bespoke market intelligence, epidemiology, real-world evidence, and patent analytics). The platform applies AI and advanced analytics to cleaned health data to support product selection, launch planning, and competitive monitoring for pharmaceutical companies, CROs, and API manufacturers.
Is InPhamed a public or private company?
InPhamed is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was InPhamed founded?
InPhamed was founded in 2021. It employs 11 to 50 people.
Where is InPhamed based?
InPhamed is headquartered in New Delhi, India, in the Asia region.
How does InPhamed make money?
Two revenue lines are on record. Subscription Access to Platform is the primary driver. The others are custom Consulting Services.
Who are InPhamed's main competitors?
Broad incumbents on record are Adis (Springer Nature), GlobalData, Clarivate Analytics, Citeline (formerly Pharma Intelligence / Informa) and Evaluate Pharma. Direct peers are PharmaCircle, IPD Analytics and DrugPatentWatch. Definitive Healthcare is listed as a regional player. Beacon Targeted Therapies is listed as an emerging player.
Does InPhamed have an API?
No public API is recorded for InPhamed.
What industry is InPhamed in?
InPhamed's product category is Pharmaceutical Intelligence Software. Its primary akta.pro industry code is HLACAIAF, Healthcare Terminology, Ontology & Code Set Management (SNOMED/LOINC/ICD/RxNorm), with a secondary code of HLACAOAO, Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines). Its NAICS code is 541910.